Identifying patient-specic prognostic biomarkers is of critical importance in developing personalized treatment for clinically and molecularly heterogeneous diseases such as cancer. In this article, we propose a novel regression framework, Bayesian hierarchical varying-sparsity regression (BEHAVIOR) models to select clinically relevant disease markers by integrating proteogenomic (proteomic+genomic) and clinical data. Our methods allow flexible modeling of protein-gene relationships as well as induces sparsity in both protein-gene and protein-survival relationships, to select genomically driven prognostic protein markers at the patient-level. Simulation studies demonstrate the superior performance of BEHAVIOR against competing method in terms of both protein marker selection and survival prediction. We apply BEHAVIOR to The Cancer Genome Atlas (TCGA) proteogenomic pan-cancer data and several interesting prognostic proteins and pathways that are shared across multiple cancers and some that exclusively pertain to specific cancers.
Bayesian Hierarchical Varying-Sparsity Regression Models with Application to Cancer Proteogenomics / Ni Y.; Stingo F.C.; Ha M.J.; Akbani R.; Baladandayuthapani V.. - In: JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION. - ISSN 0162-1459. - STAMPA. - 114:(2019), pp. 48-60. [10.1080/01621459.2018.1434529]
Bayesian Hierarchical Varying-Sparsity Regression Models with Application to Cancer Proteogenomics
Stingo F. C.;
2019
Abstract
Identifying patient-specic prognostic biomarkers is of critical importance in developing personalized treatment for clinically and molecularly heterogeneous diseases such as cancer. In this article, we propose a novel regression framework, Bayesian hierarchical varying-sparsity regression (BEHAVIOR) models to select clinically relevant disease markers by integrating proteogenomic (proteomic+genomic) and clinical data. Our methods allow flexible modeling of protein-gene relationships as well as induces sparsity in both protein-gene and protein-survival relationships, to select genomically driven prognostic protein markers at the patient-level. Simulation studies demonstrate the superior performance of BEHAVIOR against competing method in terms of both protein marker selection and survival prediction. We apply BEHAVIOR to The Cancer Genome Atlas (TCGA) proteogenomic pan-cancer data and several interesting prognostic proteins and pathways that are shared across multiple cancers and some that exclusively pertain to specific cancers.File | Dimensione | Formato | |
---|---|---|---|
Jasa2018_Protogenomics.pdf
Accesso chiuso
Tipologia:
Versione finale referata (Postprint, Accepted manuscript)
Licenza:
Tutti i diritti riservati
Dimensione
1.97 MB
Formato
Adobe PDF
|
1.97 MB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.